News

Regeneron's Pipeline Hit By Catalent Delays, But Dupixent Shines
On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...
Rash of tariff letters unnerve investors with banks worst hit as markets drop
European stocks logged their biggest one-day drop in over three months on Friday as investors grappled with the repercussions ...
Asianet Newsable on MSN40m
Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare
The Washington Post reported on Friday that state Medicaid programs and Medicare Part D insurance plans will be able to ...
Trump’s Weight-Loss Experiment Could Aid Lilly, Novo. Cost Is Still a Problem.
The Washington Post reported the CMS is considering a plan that could allow Medicare plans to pay for the drugs.